Ann: OLE Study update reveals impressive Survival Data, page-111

The good Dr T has delivered:

• knowledge with regard to drug discovery, development, regulation and commercialisation as well as FDA and TGA processes, requirements and regulations
• engagement with potential investors/BP through worldwide meetings, seminars and conferences
• greater awarenessabout the company, locally and internationally
• clear, concise, transparent and focused messaging (presentations, ASX announcements, webinars)
• engagement with the world’s premierregulatory agency, the FDA, that has resulted in theCompany being granted a Pre-Investigational New Drug meeting and Orphan Drug Designation for MPL
• a successful capital raise at a premium in late 2023
• SAB
• key partnerships including Berry Consultants (clinical study design and statistical analysis specialists)
• Investor hub (public)
• Mr John Clark (Chief Operating Officer) and Dr Nicky Wallis (Chief Scientific Officer)
• change in corporate direction from cancer (canine/human) to neurodegenerative diseases which provide nearer term commercialization possibilities for MPL
• a professional, transparent, cohesive, active and commercially focused board and management
• shareholder confidence (except for @Buckland of course) through strong shareholder relations
• Board room peace

I think we should name you Monty Python: “Apart from the sanitation, medicine, education, wine, public order, irrigation, roads, the fresh water system, and public health ... what have the Romans ever done for us?Brought peace!”

What has MT ever done for PAA? Brought peace!